Suppr超能文献

BEAM 和 HD-l-PAM 200mg/m(2) 自体造血干细胞移植后口腔粘膜炎的危险因素和冷冻疗法的疗效。

The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation.

机构信息

University Hospital Pilsen, Haematology-Oncology, Plzen, Czech Republic.

出版信息

Eur J Oncol Nurs. 2011 Dec;15(5):508-12. doi: 10.1016/j.ejon.2011.01.006. Epub 2011 Feb 10.

Abstract

PURPOSE

Oral mucositis (OM) still represents a significant complication of hematopoietic stem cell transplantations (HSCT). Observational studies focusing on risk factor definitions are still warranted.

METHOD

A total of 126 patients participated in this observational study after autologous HSCT with the BEAM and HD-l-PAM 200mg/m(2) conditioning regimens. Basic clinical and laboratory variables and their impact on OM were assessed.

RESULTS

Age, gender, body mass index, and baseline absolute neutrophil counts were not shown to have any negative impact on OM development. The multivariate analysis revealed oral cryotherapy non-provision as being the most significant predictor for OM incidence (p < 0.0001), followed by BEAM conditioning regimen (p = 0.007), OM in a patient's history (p = 0.002) and lower number of days since the last chemotherapy (p = 0.025). The cryotherapy was remarkably effective both in the single high-dose melphalan 200mg/m(2) conditioning regimen (18% OM in cryotherapy vs. 68% without it, p<0.0001) and in the multidrug BEAM (melphalan 140mg/m(2)) regimen (38% vs. 86%, p=0.006).

CONCLUSION

Oral cryotherapy should be implemented into supportive care management in patients treated with high-dose melphalan short-infusion chemotherapy. Large and well-designed randomized trials are necessary to obtain more significant and reliable results and understanding regarding OM risk factors.

摘要

目的

口腔黏膜炎(OM)仍然是造血干细胞移植(HSCT)的一个严重并发症。目前仍需要对重点关注危险因素定义的观察性研究进行评估。

方法

共有 126 例患者在接受自体 HSCT 联合 BEAM 和 HD-l-PAM200mg/m²预处理方案后参与了这项观察性研究。评估了基本的临床和实验室变量及其对 OM 的影响。

结果

年龄、性别、体重指数和基线绝对中性粒细胞计数对 OM 发展没有负面影响。多变量分析显示,口腔冷冻疗法的非应用是 OM 发生率的最显著预测因素(p < 0.0001),其次是 BEAM 预处理方案(p = 0.007)、患者病史中的 OM(p = 0.002)和化疗结束后时间较短(p = 0.025)。冷冻疗法在单剂量高剂量美法仑 200mg/m²预处理方案(冷冻疗法组 OM 发生率为 18%,无冷冻疗法组为 68%,p < 0.0001)和多药 BEAM(美法仑 140mg/m²)方案中均具有显著疗效(38% vs. 86%,p = 0.006)。

结论

对于接受高剂量美法仑短输注化疗的患者,应将口腔冷冻疗法纳入支持性护理管理中。需要进行大型和精心设计的随机试验,以获得有关 OM 危险因素的更显著和可靠的结果和认识。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验